- Home
- LGL vs BCAB Comparison
LGL vs BCAB Comparison
Compare LGL & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGL
- BCAB
- Stock Information
- Founded
- LGL 1917
- BCAB 2007
- Country
- LGL United States
- BCAB United States
- Employees
- LGL N/A
- BCAB N/A
- Industry
- LGL Industrial Machinery/Components
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- LGL Technology
- BCAB Health Care
- Exchange
- LGL Nasdaq
- BCAB Nasdaq
- Market Cap
- LGL 31.5M
- BCAB 33.5M
- IPO Year
- LGL N/A
- BCAB 2020
- Fundamental
- Price
- LGL $6.26
- BCAB $0.69
- Analyst Decision
- LGL
- BCAB Buy
- Analyst Count
- LGL 0
- BCAB 2
- Target Price
- LGL N/A
- BCAB $5.00
- AVG Volume (30 Days)
- LGL 2.4K
- BCAB 895.9K
- Earning Date
- LGL 11-13-2024
- BCAB 11-07-2024
- Dividend Yield
- LGL N/A
- BCAB N/A
- EPS Growth
- LGL 66.76
- BCAB N/A
- EPS
- LGL 0.07
- BCAB N/A
- Revenue
- LGL $4,130,000.00
- BCAB $11,000,000.00
- Revenue This Year
- LGL N/A
- BCAB N/A
- Revenue Next Year
- LGL N/A
- BCAB N/A
- P/E Ratio
- LGL $90.88
- BCAB N/A
- Revenue Growth
- LGL 26.49
- BCAB N/A
- 52 Week Low
- LGL $4.86
- BCAB $0.67
- 52 Week High
- LGL $6.76
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- LGL 58.05
- BCAB 19.59
- Support Level
- LGL $5.88
- BCAB $1.17
- Resistance Level
- LGL $5.95
- BCAB $1.72
- Average True Range (ATR)
- LGL 0.11
- BCAB 0.13
- MACD
- LGL 0.01
- BCAB -0.06
- Stochastic Oscillator
- LGL 96.90
- BCAB 2.12
About LGL LGL Group Inc. (The)
LGL Group Inc is a holding company engaged in services, merchant investment and manufacturing business activities. The company has two reportable segments; Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.